Assembling evidence grade
Loading
Independent evidence before payment.
Triple GIP/GLP-1/glucagon agonist · also: LY3437943
Retatrutide carries an Evidence Grade of B (High confidence). The strongest published evidence catalogued is human rct / review.
Grade B rule: One human RCT, Phase-2-only RCTs, or three or more other human studies.
The grade reflects the strength of the published evidence, not safety or efficacy. “Confidence” means how settled that grade is given the record — not how likely the compound is to work.
Human-use stop
This compound is investigational, warned or not approved for human use. A seller calling it “research only,” showing testimonials, registering a company or publishing a COA does not create an approved consumer medicine. Seller links below are market-surveillance records, not recommendations.
Retatrutide is an investigational triple receptor agonist with published Phase 2 randomised data. It is earlier in development than semaglutide or tirzepatide.
Animal and in-vitro results are shown separately and must never be read as established human outcomes.
In plain terms: there are 6 randomised human trials here — the strongest kind of evidence. That is about the research, not about any particular seller or batch.
Strongest: randomised or pooled human trials.
Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA. Obesity (Silver Spring, Md.), 2025.
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Annals of internal medicine, 2025.
Emerging pharmacotherapies for obesity: A systematic review. Pharmacological reviews, 2025.
Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nature medicine, 2024.
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet (London, England), 2023.
Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial. The New England journal of medicine, 2023.
Observational, open-label or small human studies.
none catalogued
Preclinical animal models — not a human outcome.
none catalogued
Cell / tissue studies — not a human outcome.
none catalogued
Proposed mechanism — hypothesis, not evidence of effect.
Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes, obesity & metabolism, 2026.
Retatrutide-A Game Changer in Obesity Pharmacotherapy. Biomolecules, 2025.
Gut hormones and appetite regulation. Current opinion in endocrinology, diabetes, and obesity, 2024.
Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition?. Diabetes care, 2024.
Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes care, 2024.
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell metabolism, 2022.
On “cited by N”: citation counts (Crossref) reflect how often a paper has been referenced — a measure of academic attention, not of validity, safety, or whether a compound works. They do not affect the Evidence Grade, which is set purely by the strength of the evidence tier.
No approved formulation exists. Long-term safety is not established and Phase 3 results are pending. Findings are investigational.
An investigational drug studied in trials but with no approved formulation in major markets. There is no legal consumer route; anything sold is unapproved material of unverified identity, purity and dose.
PepCred flags any vendor selling this compound to the public as a consumer-protection concern. Status reflects regulator records; see the regulatory detail below.
Sample of 8 (not ranked) — see all on ClinicalTrials.gov:
No FDA-approved (US) drug labelling found for this compound. A search of openFDA returned no approved product containing it as an active ingredient.
This reflects US FDA approval only — other regulators (e.g. MHRA, EMA) may differ; see the note below. Absence of an approved label is not, by itself, a safety finding, and a “research use only” label does not establish safety, legality or correct identity.
PepCred note: Investigational — no marketing authorisation.
FDA confirms retatrutide is investigational with no approved formulation.
These unranked records show where the name was detected. For an investigational, warned or unapproved compound, no seller, company registration, review score or COA creates an approved human-use route.
None of these is verified for human use.